Supply Chain Intelligence

Cabaletta Bio, Inc. Supply Chain

CABA supply chain intelligence for Cabaletta Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

CABA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
1Customers
3Debt Items
20Related Chains

Cabaletta Bio, Inc. Suppliers

TickerNameConfidenceEvidence
CANTOR-FITZGERALD-CO CANTOR-FITZGERALD-CO 90% On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgeral…
GUGGENHEIM-SECURITIES-LLC GUGGENHEIM-SECURITIES-LLC 90% On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgeral…
LONZA LONZA 90% In December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of the Company's cell processing manufacturing partners
MINARIS MINARIS 90% In August 2023, and as extended in August 2024, the Company entered into work orders under the Minaris Agreement for Minaris to serve as a cell processing manufacturing partner for the MusCAARTes TM …
TD-SECURITIES-USA-LLC TD-SECURITIES-USA-LLC 90% On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgeral…

Cabaletta Bio, Inc. Customers

TickerNameConfidenceEvidence
KYTX Kyverna Therapeutics, Inc. 72% Reciprocal relationship from KYTX graph: a have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (i) any breach of our respective repr…

Cabaletta Bio, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CABA-DEBT-16538 Warrants outstanding: 3090190 90% xbrl warrant detail from xbrl 2026-03-31.
CABA-DEBT-8446 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
CABA-DEBT Debt stack $26.4M 90% Market cache reports total debt of $26.4M.

Cabaletta Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cabaletta Bio, Inc..

Cabaletta Bio, Inc. Ownership

HolderNameConfidenceEvidence
CABA-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME T. Rowe Price Investment Management, Inc. 90% 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 112 tracked holders.

Cabaletta Bio, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ELVN Enliven Therapeutics, Inc. 100.00 2
BIAF bioAffinity Technologies, Inc. 100.00 2
CAH Cardinal Health, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CRIS Curis, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AVIR Atea Pharmaceuticals, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
ATYR aTyr Pharma, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
TECX Tectonic Therapeutic, Inc. 100.00 2
VERA Vera Therapeutics, Inc. 100.00 2
CGEM Cullinan Therapeutics, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
ALMS Alumis Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
View CABA supply chain intel →

Explore the full interactive supply chain map for Cabaletta Bio, Inc..

Open CABA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map